AbbVie receives Health Canada approval for Ubrelvy tablet to treat migraines | Tech Reddy

[ad_1]


MT Newswires 2022

All news about ABBVIE INC.

Analyst Recommendations on ABBVIE INC.

Sale 2022 58 298 M

Net income 2022 13 952 M

Net debt 2022 54 043 M

P/E ratio 2022 18.4x
Harvest 2022 3.73%
Capitalization 271 B
271 B
EV / Sales 2022 5.57x
EV / Sales 2023 5.81x
Number of employees 50,000
Free-Float 97.4%


Duration:

Period:




AbbVie Inc.  Technical Analysis Chart |  MarketScreener

Technical Analysis Areas ABBVIE INC.

Short term Medium term A long time
Trends Neutral Neutral Neutral

Evolution of the Income Statement

Sat

Buy in

Average consensus PRIVILEGE
Number of analysts 24
Final closing price $153.04
Average target price $157.40
Spread / Average Target 2.85%


[ad_2]

Source link